A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study is a randomized, open-label, multicenter Phase III clinical trial evaluating patients with EGFR-mutant locally advanced or metastatic NSCLC. The Phase III study is planned to enroll approximately 450 participants, who will be randomized in a 1:1 ratio into the following groups: Experimental group: SYS6010 + Osimertinib Control group: Osimertinib
Epistemonikos ID: 44210dbf59f09aed25bfe0447ee9dec3b1a5a922
First added on: Jan 30, 2026